⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
NUCB2 in Ovarian Aging / POI
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-28 — Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.: Proteomic MR/colocalization nominated NUCB2 as a causal POI target, with dysregulation replicated in mouse and human granulosa-cell injury models; positioned as diagnostic and druggable candidate pending in vivo validation. [human-observational] (novelty: 3)
Open questions
Related
Contributing findings
Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.
28-aug-2026
novelty 3
per-area 3
strengthens